SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database-Reference-Cited by-同舟云学术

SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database

Published:2020-08-21 Issue:2 Volume:61 Page:187-192
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

García Montserrat¹,Arteche‐Martinez Unai²,Lertxundi Unax³,Aguirre Carmelo¹⁴

Affiliation:

1. Biocruces Bizkaia Health Research Institute Osakidetza Basque Health Service Galdakao‐Usansolo Hospital Basque Country Pharmacovigilance Unit Galdakao Spain

2. Osakidetza Basque Health Service Primary Health Centre Lakua‐Arriaga Vitoria‐Gasteiz Spain

3. Bioaraba Health Research Institute Osakidetza Basque Health Service, Araba Mental Health Network Araba Psychiatric Hospital, Pharmacy Service Vitoria‐Gasteiz Spain

4. Department of Pharmacology School of Medicine and Nursing University of the Basque Country Leioa Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1722

Reference22 articles.

1. Diabetes and Cancer: A consensus report

2. US Food and Drug Administration.FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone. Accessed May 19 2020.

3. Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis

4. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

5. Center for Drug Evaluation and Research. Application number: 2022930Org1s000.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000SumR.pdf. Published 2013. Accessed November 8 2019.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors;JACC: CardioOncology;2024-04

2. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential;Frontiers in Pharmacology;2024-03-26

3. SGLT2 inhibition and three urological cancers: Up‐to‐date results;Diabetes/Metabolism Research and Reviews;2024-03

4. Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization;Diabetes, Obesity and Metabolism;2024-02-14

5. Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials;Frontiers in Pharmacology;2024-01-11